Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone Kuss, Sharon R. Jackson, carol moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Cathy Zhou, Edith Szafer-Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia

Research output: Contribution to journalMeeting Abstractpeer-review

Fingerprint

Dive into the research topics of 'Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study'. Together they form a unique fingerprint.

Medicine & Life Sciences